My 5 Favorite Dividend Stocks to Buy Right Now

Key numbers: Realty Income yields 5% with 55+ years of monthly dividends and 133 increases, owning ~15,500 properties generating $5.3B in annualized rent; ExxonMobil produced $52B cash from operations in 2025, paid $17.2B in dividends and repurchased $20B of shares (yield 2.8%); AbbVie reported Q4 drivers Skyrizi $5.0B (+31.9%) and Rinvoq $2.37B (+28.6%) with quarterly revenue $16.6B (+10% YoY, yield 3%). Coca-Cola remains a Dividend King with a 2.6% yield and broad non-soda beverage exposure. JPMorgan’s JEPQ ETF uses covered calls/ELNs to deliver a 10.6% current yield monthly, providing high income from tech-heavy holdings but with capped upside versus owning the underlying names.

Analysis

Income-seeking flows are bifurcating into two distinct strategies: direct cash-yield assets (high-quality REITs, energy integrators) and option-overlay products that monetize volatility. That bifurcation has a second-order effect of compressing realized volatility in large-cap tech (more option supply), which lowers implied vols and creates cheaper entry points for directional longs while simultaneously capping upside for passive buyers of ETFs that sell premium.

Macro and idiosyncratic catalysts will dominate outcomes over different horizons. REIT/real estate exposure is most sensitive to 10yr yield moves on a three-to-twelve month horizon (a +75–100bp move historically knocks 10–20% off consensus NAV multiples), while energy and pharma outcomes hinge on commodity swings and discrete clinical/regulatory readouts over similar windows. Covered-call products are vulnerable inside multi-week rallies — a single strong tech re-acceleration can produce double-digit NAV drawdowns even as income accrues.

A pragmatic, contrarian play is to synthetically replicate the ETF income profile but retain upside optionality: own underlying quality tech names and sell a tight, rules-based call overlay (10–15% OTM, monthly) rather than buying a packaged product that passively caps you. Also consider rotating a portion of traditional dividend allocations from defensive staples into higher FCF growers with active buyback optionality — you get asymmetric upside if profits surprise and downside protection via repurchase cadence.

Key Decisions for Investors

• Long ABBV shares for 6–18 months (target total return 20–30%); buy a 1yr 20% OTM protective put sized to cap downside to ~15%. Rationale: asymmetric upside from drug growth + capital returns; risk = regulatory/clinical setbacks that could cost more than 15% in months.
• Long O (Realty Income) 6–12 month position sized as income sleeve; hedge duration risk by buying a 9–12 month 10% OTM put (or reduce position if 10yr >4%). Rationale: monthly cash flow reduces cash drag but is rate-sensitive; risk/reward favors holding below a 15% NAV haircut scenario.
• Construct an in-house covered-call overlay on a tech mini-basket (NVDA, MSFT, AAPL) instead of buying JEPQ: buy equal-weighted shares and sell 1-month calls 10–15% OTM, roll monthly. Expected yield boost ~6–10% p.a. while preserving meaningful upside; risk = abrupt rallies where calls cap short-term gains.
• Pair trade: long ABBV / short KO (matched notional) for 9–12 months. Rationale: tilt from defensive, lower-growth income to higher FCF & buyback-driven income; target pair returns +15% if ABBV outperforms KO by 12–15%; risk = equal-weight macro shock (rates/consumption) that hurts both equally.